Novanta Inc. (NOVT), headquartered in Bedford, Massachusetts, is a leading global supplier of technology solutions for medical and industrial applications. The company has a rich history and a promising presence on the technology market, operating in over 25 locations across Europe, Asia, and North America.
The foundation of Novanta Inc. dates back to 1968, when the corporation started as Cambridge Technology Inc., focusing on developing and delivering innovative laser products and systems. Over the years, Novanta has grown through strategic acquisitions and expansion into new technology sectors. Today, the company is known as a trusted provider of advanced healthcare solutions and plays a significant role in driving advancements in various sectors like medical technology, robotics, industrial, and data processing.
Novanta Inc. operates through three primary business units: Vision Technologies, Photonics, and Precision Motion. This diversified structure allows the company to cater to a wide range of industries, including healthcare, industrial technology, and Material Processing.
Vision Technologies business focuses on providing medical devices and imaging solutions for Original Equipment Manufacturers (OEMs). This includes components and subsystems that go into health care and life sciences equipment to help improve patient care and safety.
The Photonics segment generates practical applications of light, mainly laser technology. It has a wide variety of uses, from research Laboratories to manufacturing industries, and even in aerospace and defense organizations.
The Precision Motion sector designs and produces highly specialized motor and motion control solutions. These systems find use in robotics, automation, and machine tools, used across an array of high precision and high-reliability applications.
Innovation and quality are fundamental pillars to Novanta Inc.'s success. The company is committed to investment in research and development, to deliver superior, cutting-edge technology solutions. Customer-focus is also a key aspect of Novanta’s strategy. By building close relationships with their clients, the company can adapt to ever-evolving market needs and enhance value for its stakeholders.
Novanta Inc. symbolizes excellent strategic vision and efficient implementation, making it a force to be reckoned with in the technology sector. The company’s financial performance is reflective of its strong market standing, consistently reporting solid revenue growth and robust profits.
Overall, Novanta Inc. is not only a technology industry leader but a transformational force, making contributions towards creating a better future. The company brings value to society by helping its customers improve productivity, enhance quality, and increase safety within their respective industries. It's a company that thrives on the belief that innovation and collaboration are keys to shaping a better world.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Novanta reported a 23% increase in third-quarter 2026 GAAP revenue to $305 million, partly due to its largest acquisition, Riverpoint Medical. While GAAP net income decreased, adjusted EBITDA rose by 38%, and the company raised its full-year 2026 guidance, reflecting positive impacts from the acquisition. However, GAAP profit margins remained thin, and GAAP operating income declined.
Novanta (NOVT), a medicine and manufacturing technology provider, is set to report its Q3 earnings, with analysts expecting a 21.5% year-on-year revenue growth. The company previously exceeded revenue expectations last quarter, and its EBITDA and revenue guidance also surpassed analyst forecasts. While Novanta has missed revenue estimates multiple times in the past two years, analysts have generally maintained their estimates for the upcoming report.
Stock Traders Daily provides a liquidity mapping analysis for Novanta Inc. (NASDAQ: NOVT), indicating strong sentiment across all horizons and an overweight bias. The analysis highlights an exceptional short setup targeting 12.5% downside and offers three distinct AI-generated trading strategies: Position, Momentum Breakout, and Risk Hedging, along with multi-timeframe signal analysis.
Novanta Inc. (NASDAQ:NOVT) shares recently rose 2.3% to $144.02, crossing above their 200-day moving average of $141.92, with a high of $146.33. Despite a consensus "Hold" rating from analysts, the company exceeded quarterly expectations with $0.89 EPS on $265.81 million in revenue. Institutional investors hold a significant 98.35% of the shares.
Novanta Inc. announced that its Chief Financial Officer, Robert Buckley, and Chief Operating Officer of Medical Solutions, John Lesica, are scheduled to present at the Baird 2026 Global Industrial Conference on November 11, 2026, in Chicago, Illinois. Novanta is a global supplier of core technology solutions for medical, life science, and advanced industrial equipment manufacturers. The company's common shares are traded on Nasdaq under the ticker symbol "NOVT."
Novanta Inc. announced that its Chief Financial Officer, Robert Buckley, and Chief Operating Officer of Medical Solutions, John Lesica, are scheduled to present at the Baird 2026 Global Industrial Conference on Wednesday, November 11, 2026, in Chicago, Illinois. The company is a technology partner to medical and advanced technology equipment manufacturers, providing core technology solutions. Novanta's common shares are traded on Nasdaq under the ticker symbol "NOVT."
Novanta Inc. (Nasdaq: NOVT) will release its third quarter 2026 financial results after the U.S. financial markets close on Monday, November 9, 2026. The company will host a conference call on Tuesday, November 10, 2026, at 8:00 a.m. ET to discuss these results. A live webcast and replay will be available on the Investors section of Novanta's website.
Novanta (NOVT) stock has seen a 41.3% return over the past year, leading to a high P/E ratio of 86.5x, significantly above its industry average. This valuation suggests the market has high confidence in its future earnings and profit durability, raising questions about whether the current price is justified by its underlying earnings power. Investors are encouraged to consider the company's P/E in relation to its sector and a tailored benchmark to assess if the premium is warranted.